The JUN Knockout CAL-27 Polyclonal Cells constitute a CRISPR/Cas9-mediated polyclonal knockout cell population targeting the JUN gene in the human CAL-27 oral squamous cell carcinoma cell line. This genetic disruption ablates c-Jun protein expression, creating a loss-of-function model for studying AP-1 transcription factor activity in a cellular context relevant to head and neck cancer. The polyclonal pool provides a heterogeneous knockout background that mimics therapeutic target inhibition in a bulk tumor cell population, enabling functional genomics and drug response studies.
The CAL-27 cell line originates from the tongue of a 56-year-old male patient with squamous cell carcinoma. It exhibits epithelial morphology and retains molecular features characteristic of oral cavity tumors, including elevated basal AP-1 signaling and sensitivity to EGFR and MAPK pathway ligands. CAL-27 serves as a widely accepted in vitro model for investigating oncogenic mechanisms, tumor cell migration, and therapeutic vulnerabilities in human oral squamous cell carcinoma.
JUN encodes c-Jun, an essential subunit of the AP-1 transcription factor complex. In response to extracellular stimuli, JNK1/2/3 (MAPK8/9/10) and ERK1/2 (MAPK3/1) phosphorylate c-Jun at Ser63 and Ser73, enhancing its transactivation potential. Phosphorylated c-Jun dimerizes with FOS family members, ATF2, or JDP2 to form functional AP-1 complexes that bind TRE elements in promoter regions. This transcription factor orchestrates expression of downstream effectors including CCND1 (cyclin D1), BCL2, MMP9, VEGF, and IL-8. c-Jun activity is also modulated by cofactors such as p300/CBP and HDACs, integrating signals from MAPK, Wnt, and TGF-?? pathways to regulate proliferation, apoptosis, and stress responses.
In CAL-27 cells, c-Jun is a central mediator of the malignant phenotype. Constitutive activation of JNK and ERK pathways sustains AP-1-dependent transcription of genes promoting cell cycle progression, survival, and extracellular matrix remodeling. Disruption of JUN expression abrogates this transcriptional program, attenuating tumor cell proliferation, anchorage-independent growth, and migratory capacity. Consequently, these knockout cells provide a defined platform to dissect AP-1 contributions to oral cancer progression, evaluate functional compensation by other AP-1 members, and assess the dependency of oncogenic signaling networks on c-Jun?Cmediated transcriptional output.
Typical applications include mechanistic studies of JUN in oral squamous cell carcinoma, validation of c-Jun target genes via RNA-seq and ChIP-qPCR, and functional assays such as wound healing, apoptosis, and AP-1 luciferase reporter analysis. The polyclonal knockout population is well-suited for drug screening campaigns aimed at identifying compounds that circumvent AP-1 signaling or that exhibit synthetic lethality with JUN loss. Researchers can also combine this model with pharmacological inhibitors of upstream kinases (e.g., JNK or MEK inhibitors) to map pathway dependencies. For technical specifications, lot-specific sequence verification data, or therapeutic area consultations, please contact Ascent Research.
